Avalo Therapeutics, Inc.

AVTXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1534120

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$1.9M	$18.1M	$5.4M	$6.7M	$6.8M
Cost of Goods and Services Sold	—	$3.4M	$1.5M	$300.0K	$300.2K
Research and Development Expense	—	—	—	—	—
Selling, General and Administrative Expense	—	$20.7M	—	—	—
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$27.4M	-$37.4M	-$82.1M	-$72.8M	-$16.1M
Nonoperating Income (Expense)	-$4.2M	-$4.2M	-$2.4M	$5.7M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$21.0M	$33.4M	$80.2M	$43.8M	$36.1M
Assets, Current	$8.4M	$16.4M	$61.8M	$26.0M	$17.7M
Cash and Cash Equivalents, at Carrying Value	$7.4M	$13.2M	$54.6M	$18.9M	$3.6M
Inventory, Net	—	$20.0K	$38.0K	$3.0K	$21.3K
Liabilities	$13.7M	$44.3M	$57.1M	$19.2M	$15.1M
Liabilities, Current	$4.6M	$22.1M	$19.9M	$15.2M	$12.2M
Accounts Payable, Current	$446.0K	$2.9M	$3.4M	$2.6M	$2.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$30.7M	-$26.8M	-$70.9M	-$40.5M	-$19.1M
Net Cash Provided by (Used in) Investing Activities	-$133.0K	-$95.0K	-$113.0K	$11.1M	-$443.0K
Net Cash Provided by (Used in) Financing Activities	$25.0M	-$14.7M	$106.8M	$44.8M	$12.6M
Payments to Acquire Property, Plant, and Equipment	—	—	$113.0K	$63.0K	$262.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)